Literature DB >> 10956322

AT(1) receptor antagonists-beyond blood pressure control: possible place in heart failure treatment.

J McMurray1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10956322      PMCID： PMC1766530          DOI： 10.1136/heart.84.suppl_1.i42

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  12 in total

1.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

Authors:  B Pitt; P A Poole-Wilson; R Segal; F A Martinez; K Dickstein; A J Camm; M A Konstam; G Riegger; G H Klinger; J Neaton; D Sharma; B Thiyagarajan
Journal:  Lancet       Date:  2000-05-06       Impact factor: 79.321

2.  Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.

Authors:  C B Granger; G Ertl; J Kuch; A P Maggioni; J McMurray; J L Rouleau; L W Stevenson; K Swedberg; J Young; S Yusuf; R M Califf; B A Bart; P Held; E L Michelson; M A Sellers; G Ohlin; R Sparapani; M A Pfeffer
Journal:  Am Heart J       Date:  2000-04       Impact factor: 4.749

3.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

Authors:  J N Cohn; G Johnson; S Ziesche; F Cobb; G Francis; F Tristani; R Smith; W B Dunkman; H Loeb; M Wong
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

4.  Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.

Authors:  G A Riegger; H Bouzo; P Petr; J Münz; R Spacek; H Pethig; V von Behren; M George; H Arens
Journal:  Circulation       Date:  1999-11-30       Impact factor: 29.690

5.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.

Authors:  K Swedberg; M Pfeffer; C Granger; P Held; J McMurray; G Ohlin; B Olofsson; J Ostergren; S Yusuf
Journal:  J Card Fail       Date:  1999-09       Impact factor: 5.712

6.  Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure.

Authors:  G Hamroff; S D Katz; D Mancini; I Blaufarb; R Bijou; R Patel; G Jondeau; M T Olivari; S Thomas; T H Le Jemtel
Journal:  Circulation       Date:  1999-03-02       Impact factor: 29.690

7.  Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure.

Authors:  J N Cohn; G Tognoni; R D Glazer; D Spormann; A Hester
Journal:  J Card Fail       Date:  1999-06       Impact factor: 5.712

8.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

9.  Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan.

Authors:  K Dickstein; J Kjekshus
Journal:  Am J Cardiol       Date:  1999-02-15       Impact factor: 2.778

10.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245
View more
  2 in total

1.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2021-05-22

Review 2.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; James Thomas; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2018-06-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.